Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
Date:2/29/2008

Total liabilities 1,530,554 1,834,313

SHAREHOLDERS' EQUITY 1,354,420 1,328,232

TOTAL LIABILITIES & SHAREHOLDERS'

EQUITY $2,884,974 $3,162,545

WARNER CHILCOTT LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW

(in thousands of U.S. dollars)

(Unaudited)

Quarter Ended Year Ended

Dec-31-07 Dec-31-06 Dec-31-07 Dec-31-06

CASH FLOWS FROM OPERATING

ACTIVITIES:

Net income / (loss) $19,687 $(8,520) $28,875 $(153,510)

Adjustments to reconcile net

income / (loss) to net cash

provided by operating

activities:

Depreciation 2,892 2,171 10,250 7,177

Amortization of intangible

assets 56,169 68,300 228,330 253,425

Amortization of debt finance

costs 3,280 11,135 13,813 30,154

Stock compensation expense 1,085 1,711 6,115 17,787

Accretion of preferred stock

in subsidiary - - - 26,190

Changes in assets and

liabilities:

Decrease / (increase) in

accounts receivable, prepaid

and other assets 12,742 12,780 1,852 (22,914)

(Increase) / decrease in

inventories (621) (6,955) 12,345 (34,978)

Increase in accounts payable,

accrued expenses & other

liabilities 17,107 1,888 32,430 7,933

(Decrease) / increase in

income taxes and other, net (6,507) (11,581) 5,540 (
'/>"/>

SOURCE Warner Chilcott Limited
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2007 Financial Results
2. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
3. Warner Chilcott Announces Earnings Release Date and Conference Call for Third Quarter 2007 Financial Results
4. Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent
5. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
6. Cepheid Reports Fourth Quarter and Full Year 2007 Results
7. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
8. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
9. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
10. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
11. eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a specialty ... unmet medical needs in women,s health, today announced ... at the Cantor Fitzgerald Inaugural Healthcare Conference as ... PM EDTLocation: , Le Parker Meridien Hotel, New ... under  ,Investor, or  click here The ...
(Date:6/30/2015)... ... 30, 2015 , ... With its latest polyacrylonitrile (PAN) membrane, ... faster flow rates in comparison to nylon or polyethersulfone (PES). Its unique ... easy liquid flow while trapping particulates as small as 0.2 micron in width. ...
(Date:6/30/2015)... ... 2015 , ... Matrix Marketing Group, LLC , a leading provider of ... head up its account management department as vice president of client services. Amanda ... account management and delivery expertise to the growing Matrix Marketing Group team in Denver, ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... its Phase 1/2 clinical trial of RCT-01, being ... tendinosis, has been enrolled and their tissue biopsy ... RCT-01 is comprised of non-bulbar dermal sheath (NBDS) ...
Breaking Biology Technology:Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2New Nanofiber Membrane Provides Fast, Efficient Filtration 2Matrix Marketing Group Expands Client Services Team 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 2RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 3RepliCel Life Sciences Enrolls First Participant in Phase 1/2 Clinical Trial of RCT-01 for Chronic Achilles Tendinosis 4
... to see is based on molecules in the eye ... to visible light. Now, a new technique for ... molecules to be switched between two different configurations in ... Because the configuration changes are reversible and can be ...
... Bion Environmental,Technologies, Inc. (OTC Bulletin Board: BNET) today ... environmental,treatment technology compared to anaerobic digesters., Anaerobic ... produce energy,from livestock waste since the late 1800s. ... is still based on a biological process that,produces ...
... Premier healthcare,alliance Purchasing Partners division recently announced ... one of 15 winners,chosen for the Pinnacle ... suppliers,representing the top two percent of healthcare ... exceeds the expectations of,Premier and its members ...
Cached Biology Technology:Tethered molecules act as light-driven reversible nanoswitches 2Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 2Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 3Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 4Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 5Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 6Bion Outlines Differences between its Patented Comprehensive Livestock Environmental Treatment Technology and Anaerobic Digesters 7Premier Healthcare Alliance Honors Siemens Healthcare Diagnostics for Excellence in Supplier Performance 2Premier Healthcare Alliance Honors Siemens Healthcare Diagnostics for Excellence in Supplier Performance 3
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/15/2015)... 2015 According to a new ... (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern ... by MarketsandMarkets, The Natural Language Processing Market is expected ... 18.4% for the forecast period 2015-2020. ... igures spread   through 155 P ages ...
(Date:6/11/2015)... , June 11, 2015 Daon, a ... today that its IdentityX Mobile Authentication Platform v4.0 ... Online) Alliance is an industry consortium launched in ... for simpler, stronger authentication.  In order to receive ... a rigorous series of tests that measure compliance ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... Researchers have gained a new understanding of the way ... can be slowed via angiogenesis inhibitors that eliminate the blood ... new anti-cancer drug therapies. The results of this study have ... American Journal of Pathology. "The central role of ...
... to define the roles of microRNAs is announced today ... gives researchers access to tools to investigate the biological ... genes. mirKO is a "library" of mutant mouse ... groups of microRNA genes, have been deleted. Using these ...
... 2011, Shenzhen, China BGI, the world,s largest genomics ... Hospital, announced today that the study on frequent mutations ... of the bladder was published online in Nature ... for future studies on TCC, suggesting that aberration of ...
Cached Biology News:Researchers gain new insights into how tumor cells are fed 2New resource to unlock the role of microRNAs 2New resource to unlock the role of microRNAs 3Research discovers frequent mutations of chromatin remodeling genes in TCC of the bladder 2
... Certified USDA Research Registered OLAW Assured AAALAC ... AALAS Certified Technicians Documentation ... Upon Request Focus CRP is ... your custom immunology service needs. We ...
Normal serum collected from healthy Kunming mice....
Request Info...
QML offers standard and customized paraffin embedded tissue blocks....
Biology Products: